|
1
|
De Gregori S, Minella CE, De Gregori M,
Tinelli C, Ranzani GN, Govoni S, Allegri M and Regazzi M: Clinical
pharmacokinetics of morphine and its metabolites during morphine
dose titration for chronic cancer pain. Ther Drug Monit.
36:335–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Brien T, Christrup LL, Drewes AM, Fallon
MT, Kress HG, McQuay HJ, Mikus G, Morlion BJ, Perez-Cajaraville J,
Pogatzki-Zahn E, et al: European pain federation position paper on
appropriate opioid use in chronic pain management. Eur J Pain.
21:3–19. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leppert W: CYP2D6 in the metabolism of
opioids for mild to moderate pain. Pharmacology. 87:274–285. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuip EJ, Zandvliet ML, Koolen SL,
Mathijssen RH and van der Rijt CC: A review of factors explaining
variability in fentanyl pharmacokinetics; focus on implications for
cancer patients. Br J Clin Pharmacol. 83:294–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Y, Jackson KA, Slon B, Hardy JR, Franco
M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC and
Somogyi AA: CYP2B6*6 allele and age substantially reduce
steady-state ketamine clearance in chronic pain patients: Impact on
adverse effects. Br J Clin Pharmacol. 80:276–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith HS: Opioid metabolism. Mayo Clin
Proc. 84:613–624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Droney J, Riley J and Ross JR: Evolving
knowledge of opioid genetics in cancer pain. Clin Oncol (R Coll
Radiol). 23:418–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ross JR, Rutter D, Welsh K, Joel SP,
Goller K, Wells AU, Du Bois R and Riley J: Clinical response to
morphine in cancer patients and genetic variation in candidate
genes. Pharmacogenomics J. 5:324–336. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diatchenko L, Robinson JE and Maixner W:
Elucidation of mu-Opioid Gene Structure: How genetics can help
predict responses to opioids. Eur J Pain Suppl. 5:433–438. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klepstad P, Rakvåg TT, Kaasa S, Holthe M,
Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE and Skorpen F:
The 118 A >G polymorphism in the human mu-opioid receptor gene
may increase morphine requirements in patients with pain caused by
malignant disease. Acta Anaesthesiol Scand. 48:1232–1239. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
De Gregori M, Garbin G, De Gregori S,
Minella CE, Bugada D, Lisa A, Govoni S, Regazzi M, Allegri M and
Ranzani GN: Genetic variability at COMT but not at OPRM1 and UGT2B7
loci modulates morphine analgesic response in acute postoperative
pain. Eur J Clin Pharmacol. 69:1651–1658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reyes-Gibby CC, Shete S, Rakvåg T, Bhat
SV, Skorpen F, Bruera E, Kaasa S and Klepstad P: Exploring joint
effects of genes and the clinical efficacy of morphine for cancer
pain: OPRM1 and COMT gene. Pain. 130:25–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rakvag TT, Ross JR, Sato H, Skorpen F,
Kaasa S and Klepstad P: Genetic variation in the
catechol-O-methyltransferase (COMT) gene and morphine requirements
in cancer patients with pain. Mol Pain. 4:642008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ross JR, Riley J, Taegetmeyer AB, Sato H,
Gretton S, du Bois RM and Welsh KI: Genetic variation and response
to morphine in cancer patients: Catechol-O-methyltransferase and
multidrug resistance-1 gene polymorphisms are associated with
central side effects. Cancer. 112:1390–1403. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
SORT: The strength-of-recommendation
taxonomy. Am Fam Physician. 71:19–20. 2005.PubMed/NCBI
|
|
16
|
de Stoutz ND, Bruera E and Suarez-Almazo
M: Opioid rotation for toxicity reduction in terminal cancer
patients. J Pain Symptom Manage. 10:378–384. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benedetti C, Brock C, Cleeland C, Coyle N,
Dubé JE, Ferrell B, Hassenbusch S III, Janjan NA, Lema MJ, Levy MH,
et al: NCCN practice guidelines for cancer pain. Oncology
(Williston Park). 14:135–150. 2000.PubMed/NCBI
|
|
18
|
Scottish Intercollegiate Guidelines
Network (SIGN). Management of chronic pain. Edinburgh: SIGN; 2013.
(SIGN publication no. 136). [December, 2013]. http://www.sign.ac.uk
|
|
19
|
Ripamonti CI, Santini D, Maranzano E,
Berti M and Roila F; ESMO Guidelines Working Group, : Management of
cancer pain: ESMO clinical practice guidelines. Ann Oncol. 23 Suppl
7:vii139–vii154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pigni A, Brunelli C, Gibbins J, Hanks G,
Deconno F, Kaasa S, Klepstad P, Radbruch L and Caraceni A: Content
development for EUROPEAN GUIDELINES on the use of opioids for
cancer pain: A systematic review and expert consensus study.
Minerva Anestesiol. 76:833–843. 2010.PubMed/NCBI
|
|
21
|
King S, Forbes K, Hanks GW, Ferro CJ and
Chambers EJ: A systematic review of the use of opioid medication
for those with moderate to severe cancer pain and renal impairment:
A European Palliative Care Research Collaborative opioid guidelines
project. Palliat Med. 25:525–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Burton AW and Cleeland CS: Cancer pain:
Progress since the WHO guidelines. Pain Pract. 1:236–242. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ventafridda V, Saita L, Ripamonti C and De
Conno F: WHO guidelines for the use of analgesics in cancer pain.
Int J Tissue React. 7:93–96. 1985.PubMed/NCBI
|
|
24
|
Schug SA, Zech D and Dörr U: Cancer pain
management according to WHO analgesic guidelines. J Pain Symptom
Manage. 5:27–32. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ripamonti C and Giusti R: 21st expert
committee on the selection and use of essential medicines: Opioid
analgesics for cancer pain: fentanyl, methadone, tramadol-EML (EML
Opioids for cancer pain: A comparative overview). OMS. Available
from URL. Jan. 2018
|
|
26
|
Schug SA and Chandrasena C: Pain
management of the cancer patient. Expert Opin Pharmacother.
16:5–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dowell D, Haegerich TM and Chou R: CDC
guideline for prescribing opioids for chronic pain-united states,
2016. JAMA. 315:1624–1645. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Busse JW, Craigie S, Juurlink DN, Buckley
DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A,
Cooper L, et al: Guideline for opioid therapy and chronic noncancer
pain. CMAJ. 189:E659–E666. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lucey M; Guideline Development Group, :
Pharmacological Management of Cancer Pain in Adults-National
Clinical Guideline No. 9. Ireland. 2015.
|
|
30
|
Jara C, Del Barco S, Grávalos C, Hoyos S,
Hernández B, Muñoz M, Quintanar T, Meana JA, Rodriguez C and de Las
Peñas R: SEOM clinical guideline for treatment of cancer pain
(2017). Clin Transl Oncol. 20:97–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nielsen LM, Olesen AE, Branford R,
Christrup LL, Sato H and Drewes AM: Association between human
pain-related genotypes and variability in opioid analgesia: An
updated review. Pain Pract. 15:580–594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi Q, Cleeland CS, Klepstad P, Miaskowski
C and Pedersen NL; GeneQOL Consortium, : Biological pathways and
genetic variables involved in pain. Qual Life Res. 19:1407–1417.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hwang IC, Park JY, Myung SK, Ahn HY,
Fukuda K and Liao Q: OPRM1 A118G gene variant and postoperative
opioid requirement: A systematic review and meta-analysis.
Anesthesiology. 121:825–834. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC
and Jawan B: Human opioid receptor A118G polymorphism affects
intravenous patient-controlled analgesia morphine consumption after
total abdominal hysterectomy. Anesthesiology. 105:334–337. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nagashima M, Katoh R, Sato Y, Tagami M,
Kasai S and Ikeda K: Is there genetic polymorphism evidence for
individual human sensitivity to opiates? Curr Pain Headache Rep.
11:115–123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tammimäki A and Männistö PT:
Catechol-O-methyltransferase gene polymorphism and chronic human
pain: A systematic review and meta-analysis. Pharmacogenet
Genomics. 22:673–691. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kluetz PG, Chingos DT, Basch EM and
Mitchell SA: Patient-reported outcomes in cancer clinical trials:
Measuring symptomatic adverse events with the national cancer
institute's patient-reported outcomes version of the common
terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin
Oncol Educ Book. 35:67–73. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Andersen RL, Johnson DJ and Patel JN:
Personalizing supportive care in oncology patients using
pharmacogenetic-driven treatment pathways. Pharmacogenomics.
17:417–434. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Slatkin NE: Opioid switching and rotation
in primary care: Implementation and clinical utility. Curr Med Res
Opin. 25:2133–2150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu G, Wang L, Guo H, Lu L, Yang S, Wang
T, Guo H, Wang H, Min J, Yang K, et al: DNA repair genes XRCC1 and
ERCC1 polymorphisms and the risk of sporadic breast cancer in Han
women in the Gansu Province of China. Genet Test Mol Biomarkers.
19:387–393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu L, Katsaros D, Mayne ST, Risch HA,
Benedetto C, Canuto EM and Yu H: Functional study of risk loci of
stem cell-associated gene lin-28B and associations with disease
survival outcomes in epithelial ovarian cancer. Carcinogenesis.
33:2119–2125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu L, Risch E, Deng Q, Biglia N, Picardo
E, Katsaros D and Yu H: An insulin-like growth factor-II intronic
variant affects local DNA conformation and ovarian cancer survival.
Carcinogenesis. 34:2024–2030. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sloan PA, Donnelly MB, Schwartz RW and
Sloan DA: Cancer pain assessment and management by housestaff.
Pain. 67:475–481. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Gregori M, Diatchenko L, Belfer I and
Allegri M: OPRM1 receptor as new biomarker to help the prediction
of post mastectomy pain and recurrence in breast cancer. Minerva
Anestesiol. 81:894–900. 2015.PubMed/NCBI
|
|
45
|
Andersen S and Skorpen F: Variation in the
COMT gene: Implications for pain perception and pain treatment.
Pharmacogenomics. 10:669–684. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fladvad T, Fayers P, Skorpen F, Kaasa S
and Klepstad P: Lack of association between genetic variability and
multiple pain-related outcomes in a large cohort of patients with
advanced cancer: The European Pharmacogenetic Opioid Study (EPOS).
BMJ Support Palliat Care. 2:351–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang G, Zhang H, He F and Fang X: Effect
of the CYP2D6*10 C188T polymorphism on postoperative tramadol
analgesia in a Chinese population. Eur J Clin Pharmacol.
62:927–931. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Holthe M, Klepstad P, Zahlsen K,
Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE and Skorpen F:
Morphine glucuronide-to-morphine plasma ratios are unaffected by
the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on
chronic morphine therapy. Eur J Clin Pharmacol. 58:353–356. 2002.
View Article : Google Scholar : PubMed/NCBI
|
